Overview
Phenibut is beta-phenyl-gamma-aminobutyric acid, a GABA analog developed in the Soviet Union and used in Russia and some neighboring countries for anxiety, insomnia, vestibular complaints, and stress-related conditions. It is not a peptide, but it appears in many nootropic and peptide-user contexts because it is often discussed alongside recovery, sleep, and stress compounds.
The phenyl ring allows phenibut to cross the blood-brain barrier better than GABA. Its main pharmacology is GABA-B receptor agonism, with additional reported activity at GABA-A and beta-phenethylamine-related systems. This profile can produce calm, reduced social anxiety, muscle relaxation, and sleepiness, but also creates tolerance and withdrawal risk that can be severe after repeated use.
Phenibut is not FDA-approved for any medical indication in the United States and should not be marketed as a dietary supplement. Published case reports and reviews describe intoxication, delirium, psychosis-like withdrawal, seizures, agitation, autonomic instability, and medically supervised tapers using agents such as baclofen or benzodiazepines. This is not a casual daily sleep aid.
This guide covers phenibut as a high-risk nootropic: how it works, why occasional effects can mislead users, what dependence looks like, which drug combinations are especially unsafe, and why conservative frequency and medical support matter more than chasing a perfect dose.
Quick facts
- Mechanism
- GABA-B agonist with sedative and anxiolytic activity
- Primary use
- Anxiety and sleep research
- Evidence
- moderate
- FDA
- Not approved
- Route
- Oral capsules or powder
- Typical results
- Acute anxiolysis and sedation with tolerance risk
Chemical information
Phenibut is beta-phenyl-gamma-aminobutyric acid with a molecular mass of 179.22 g/mol and formula C10H13NO2. It is a small GABA analog rather than a peptide, but the phenyl substitution changes brain penetration and pharmacology.
How Phenibut works
Phenibut acts primarily as a GABA-B receptor agonist, similar in broad direction to baclofen but with its own pharmacokinetic and subjective profile. GABA-B activation reduces neuronal excitability, which can lower anxiety, reduce muscle tension, and promote sedation. The same pathway also adapts with repeated exposure, so escalating doses or daily use can lead to tolerance, rebound anxiety, insomnia, and withdrawal syndromes.
Adding a phenyl ring to GABA increases central nervous system penetration. Once active in the brain, phenibut reduces excitatory neurotransmission through GABA-B signaling and may also influence dopaminergic tone. This mixed subjective profile explains why some users report both calm and sociability, but it does not remove the core depressant risk.
Withdrawal appears to involve downregulated inhibitory tone and rebound excitatory activity. Case reports describe agitation, hallucinations, tremor, autonomic instability, seizures, and symptoms that can resemble serotonin syndrome or neuroleptic malignant syndrome. These reports are especially important because standard urine drug screens do not usually detect phenibut.
Phenibut's harm profile is frequency-dependent. A single exposure is different from daily use for weeks, and large recreational doses are different from prescribed use in countries where regulated products exist. In unregulated markets, powder measurement errors, mislabeled capsules, and combination with alcohol or sedatives are major real-world hazards.
- GABA-B agonism: Reduces neuronal excitability and supports anxiolytic and sedative effects
- Blood-brain barrier entry: The phenyl group improves CNS penetration compared with GABA
- Tolerance formation: Repeated exposure can rapidly reduce effect and drive dose escalation
- Withdrawal risk: Abrupt cessation after chronic use can cause severe agitation, insomnia, psychosis, and seizures
- Respiratory depressant overlap: Alcohol, opioids, benzodiazepines, and gabapentinoids increase danger
- Testing gap: Routine drug screens may miss phenibut in intoxication or withdrawal
Pharmacokinetics
Human PK data are limited compared with approved Western medicines. Reviews often cite a half-life around 5 hours, but product form, dose, renal function, and repeated exposure can change real-world duration and withdrawal timing.
| Parameter | Value | Significance |
|---|---|---|
| Primary route | Oral | Most use involves capsules or powder |
| Half-life | About 5 hours reported | Effects and withdrawal can outlast the subjective peak |
| Metabolism | Limited human data | Interaction predictions are uncertain |
| Excretion | Renal contribution reported | Kidney impairment may increase risk |
| Onset | Often 2-4 hours orally | Redosing too early can cause stacking |
| Detection | Not routine on standard screens | Clinicians may miss exposure without history |
Dosing & administration
No FDA-approved phenibut dosing exists in the United States. Internet dosing practices are not medical guidance, and unregulated powder makes accurate measurement difficult. Redosing before onset is a common route to excessive exposure.
The most important harm-reduction variable is frequency. Daily or near-daily use is strongly associated with tolerance and withdrawal reports. People who have used phenibut repeatedly should not abruptly stop high doses without medical advice, because withdrawal can become medically serious.
Phenibut should not be combined with alcohol, benzodiazepines, opioids, Z-drugs, barbiturates, GHB, baclofen, or gabapentinoids unless a clinician is managing the situation. These combinations can compound sedation, confusion, falls, and respiratory depression.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Phenibut has a legitimate medical history in some countries, but unregulated use has produced a substantial case-report literature of intoxication and withdrawal. Treat it as a dependence-forming CNS depressant, not a benign supplement.
Common
- • Sleepiness
- • Dizziness
- • Nausea
- • Headache
- • Loss of coordination
- • Rebound anxiety after repeated use
Serious / potential risks
- • Dependence and severe withdrawal
- • Respiratory depression when combined with sedatives
- • Delirium, hallucinations, or psychosis-like symptoms
- • Seizures during intoxication or withdrawal
- • Accidental overdose from powder measurement errors
Drug interactions
Interaction evidence is mostly mechanistic and case-based, but CNS depressant combinations are clearly high risk.
| Medication | Interaction | Recommendation |
|---|---|---|
| Alcohol | Additive CNS and respiratory depression | Avoid |
| Benzodiazepines | Increased sedation, blackouts, and dependence complexity | Avoid unless medically supervised |
| Opioids | Higher overdose and respiratory depression risk | Avoid |
| Gabapentin or pregabalin | Overlapping depressant and dizziness effects | Use caution; avoid recreational stacking |
| Baclofen | Overlapping GABA-B agonism | Use only in clinician-directed taper plans |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Online nootropic vendors | Variable powder or capsule pricing | Regulatory and quality risk can be substantial |
| Prescription markets outside the US | Country-specific | Products may be regulated where legally prescribed |
| Clinical care for withdrawal | Potentially high | Severe withdrawal may require emergency or inpatient care |
The bottom line
Phenibut can produce real anxiolytic and sedative effects, but that benefit is tied to a real dependence and withdrawal liability. It is not FDA-approved in the US, should not be treated as a harmless supplement, and becomes most dangerous when used frequently or combined with other depressants.
Best for
- • Researchers studying GABA-B anxiolytic pharmacology
- • Clinicians recognizing unusual withdrawal syndromes
- • Users evaluating nootropic risks realistically
- • Occasional-use risk discussions under medical context
Not for
- • Daily anxiety self-treatment
- • Combining with alcohol or sedatives
- • People with substance use disorder vulnerability
- • Unsupervised withdrawal after chronic use
Related compounds
Pancragen
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenibut FAA
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenylpiracetam
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Pielotax
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Frequently asked questions
References
- [1] Lapin I. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Reviews (2001). doi: 10.1111/j.1527-3458.2001.tb00211.x PMID: 11830761
- [2] Hardman MI, Sprung J, Weingarten TN. Acute phenibut withdrawal: A comprehensive literature review and illustrative case report. Bosnian Journal of Basic Medical Sciences (2019). doi: 10.17305/bjbms.2018.4008
- [3] Joshi YB, Friend SF, Jimenez B, Steiger LR. Dissociative Intoxication and Prolonged Withdrawal Associated With Phenibut: A Case Report. Journal of Clinical Psychopharmacology (2017). doi: 10.1097/JCP.0000000000000731 PMID: 28614159
- [4] Ahuja T, Mgbako O, Katzman C, Grossman A. Phenibut (beta-Phenyl-gamma-aminobutyric Acid) Dependence and Management of Withdrawal. Journal of Addiction Medicine (2018). PMID: 29854531
- [5] Gurley BJ, Koturbash I. Phenibut: A drug with one too many buts. Basic & Clinical Pharmacology & Toxicology (2024). doi: 10.1111/bcpt.14075 PMID: 39197876
- [6] World Health Organization Expert Committee on Drug Dependence. Critical Review Report: Phenibut. World Health Organization (2021).